Aptorum Group Limited (NASDAQ:APM) Short Interest Update

Aptorum Group Limited (NASDAQ:APM) was the target of a large decrease in short interest during the month of December. As of December 15th, there was short interest totaling 10,748 shares, a decrease of 59.1% from the November 30th total of 26,279 shares. Currently, 0.5% of the shares of the stock are sold short. Based on an average trading volume of 42,165 shares, the short-interest ratio is currently 0.3 days. Based on an average trading volume of 42,165 shares, the short-interest ratio is currently 0.3 days. Currently, 0.5% of the shares of the stock are sold short.

Aptorum Group Stock Up 2.7%

NASDAQ:APM opened at $1.15 on Friday. The stock’s fifty day moving average price is $1.37 and its two-hundred day moving average price is $1.51. Aptorum Group has a 52-week low of $0.69 and a 52-week high of $7.49.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aptorum Group in a research report on Monday. Wall Street Zen raised Aptorum Group from a “sell” rating to a “hold” rating in a report on Saturday, October 11th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

Aptorum Group Company Profile

Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.

The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.